scholarly journals Serum exosomal miR-451a acts as a candidate marker for pancreatic cancer

2022 ◽  
pp. 172460082110700
Author(s):  
Jia Chen ◽  
Dongting Yao ◽  
Weiqin Chen ◽  
Zhen Li ◽  
Yuanyuan Guo ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Patients ◽  
Diagnostic Marker ◽  
Clinical Stage ◽  
Benign Disease ◽  
Diagnostic Efficiency ◽  
Healthy Individuals ◽  
Serum Samples ◽  
Exosomal Mirnas ◽  
Serum Exosomes

Objectives The aim of this study was to explore the diagnostic efficiency of serum exosomal miR-451a as a novel biomarker for pancreatic cancer. Methods Serum samples were collected prior to treatment. First, we analyzed microRNA (miRNA) profiles in serum exosomes from eight pancreatic cancer patients and eight healthy volunteers. We then validated the usefulness of the selected exosomal miRNAs as biomarkers in another 191 pancreatic cancer patients, 95 pancreatic benign disease (PB) patients, and 90 healthy controls. Results The expression of miR-451a in serum-derived exosomes from pancreatic cancer patients was significantly upregulated compared with those from PB patients and healthy individuals. Serum exosomal miR-451a showed excellent diagnostic power in identifying pancreatic cancer patients. In addition, exosomal miR-451a showed a significant association with clinical stage and distant metastasis in pancreatic cancer, and the expression level of serum exosomal miR-451a was sensitive to therapy and relapse. Conclusions Serum exosomal miR-451a might serve as a novel diagnostic marker for pancreatic cancer.

scholarly journals Differential Expression of Serum Exosomal miRNAs in Breast Cancer Patients and Healthy Controls

2021 ◽  
Author(s):  
Rahim Asgari ◽  
Jafar Rezaie
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Circulatory System ◽  
Health Concern ◽  
Healthy Controls ◽  
Flow Cytometry Analysis ◽  
Breast Cancer Patients ◽  
Serum Samples ◽  
Exosomal Mirnas ◽  
And Control

Purpose: Breast cancer has become as a serious public health concern worldwide. Breast cancer cells release exosomes into the circulatory system, which are easily accessible for further analysis like cancer diagnosis. In this study, we aimed to investigate expression of circulating exosomal miRNAs (miRs) in the serum of individuals with breast cancer and healthy controls. Methods: Exosomes were collected from serum samples using a commercial kit and characterized by scanning electron microscopy (SEM) and flow cytometry analysis. Expression of miRs such as miR-21, miR-155, miR-182, miR-373, and miR-126 were evaluated by real-time PCR. Results: The result showed that the expression level of exosomal miR-21, miR-155, miR-182, and miR-373 in the serum of breast cancer patients was higher than of those controls (P<0.05). However, expression of miR-126 did not change between breast cancer and control individuals (P>0.05). Conclusion: Our results showed a different miRs expression pattern between breast cancer and healthy samples, supposing potential biomarkers for breast cancer. Further studies focusing on these miRs are required to confirm our findings.

The early diagnostic value of combined detection of plasma miR-181b, miR-196a and miR-210 in pancreatic cancer

2019 ◽  
Author(s):  
Gongpan Liu ◽  
Cunhua Shao ◽  
Anyun Li ◽  
Xiaobin Zhang ◽  
Xingjun Guo ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Early Diagnosis ◽  
Operating Characteristic ◽  
Clinical Stage ◽  
Diagnostic Value ◽  
Carbohydrate Antigen ◽  
Healthy Individuals ◽  
Diagnostic Efficacy ◽  
Lymph Nodes Metastasis ◽  
Combined Detection

Abstract Background This study aimed to investigate the effect of combination of plasma miR-181b, miR-196a and miR-210 on early diagnosis of pancreatic cancer (PC).Methods In our study, the plasma was isolated from patients with PC and healthy individuals, respectively. The expressions of miR-181b, miR-196a and miR-210 were detected by qRT-PCR. Moreover, the level of carbohydrate antigen 199 (CA199) was measured by electrochemiluminescence (ECL) assay. Furthermore, the area under the receiver operating characteristic (ROC) curve (AUC) was used to analyze the diagnostic efficacy of miR-181b, miR-196a, miR-210 and CA199, as well as the combination of thses miRNAs in early PC patients and healthy individuals.Results The expressions of miR-181b, miR-196a and miR-210 were significantly upregulated in PC patients. In addition, the level of CA199 was also significantly upregulated in the plasma of PC patients. The expressions of miR-181b, miR-196a and miR-210 were closely associated with lymph nodes metastasis, clinical stage and vascular invasion, but had no correlation with the patient's age, gender and tumor size. Moreover, miR-181b, miR-196a and miR-210 have lower AUC than CA199 in PC patients. The combinations miR-181b + miR-196a, miR-181b + miR-210, miR-196a + miR-210 also have lower AUC than CA199 in PC patients. It is worth noting that the combinations miR-181b + miR-196a + miR-210 have higher AUC than CA199 in PC.Conclusions Our study demonstrated that the combination of plasma miR-181b, miR-196a and miR-210 had good value for PC early diagnosis.

scholarly journals Diagnostic Value of Plasma miR-181b, miR-196a, and miR-210 Combination in Pancreatic Cancer

2020 ◽  
Vol 2020 ◽  
pp. 1-6
Author(s):  
Gongpan Liu ◽  
Cunhua Shao ◽  
Anyun Li ◽  
Xiaobin Zhang ◽  
Xingjun Guo ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Vascular Invasion ◽  
Operating Characteristic ◽  
Clinical Stage ◽  
Diagnostic Value ◽  
Carbohydrate Antigen ◽  
Plasma Samples ◽  
Healthy Individuals ◽  
Qrt Pcr ◽  
Node Metastasis

Purpose. This study was aimed at investigating the roles of plasma miR-181b, miR-196a, and miR-210 in the diagnosis of pancreatic cancer (PC). Methods. Plasma samples were isolated from 40 patients with PC and 40 healthy individuals, respectively. The expression of miR-181b, miR-196a, and miR-210 was detected by qRT-PCR. The level of carbohydrate antigen 199 (CA199) was measured by an electrochemiluminescence (ECL) assay. The receiver operating characteristic (ROC) curve was used to analyze the diagnostic value of miR-181b, miR-196a, miR-210, CA199, and their combinations in PC. Results. The expression of plasma miR-181b, miR-196a, and miR-210 was significantly upregulated in PC patients. The plasma level of CA199 was also significantly increased in PC patients. The expression of miR-181b, miR-196a, and miR-210 was closely associated with lymph node metastasis, clinical stage, and vascular invasion but not correlated with age, gender, and tumor size. miR-181b, miR-196a, and miR-210 have lower AUC than CA199 in the diagnosis of PC. miR-181b+miR-210 and miR-196a+miR-210 also have lower AUC than CA199. It is worth noting that miR-181b+miR-196a+miR-210 has a higher AUC than CA199 in the diagnosis of PC. Conclusion. The combination of plasma miR-181b, miR-196a, and miR-210 had a good diagnostic value for PC.

scholarly journals Survival Benefit of Metformin Adjuvant Treatment For Pancreatic Cancer Patients: a Systematic Review and Meta-Analysis

2018 ◽  
Vol 49 (3) ◽  
pp. 837-847 ◽  
Author(s):  
Guoxing Wan ◽  
Xue Sun ◽  
Fang Li ◽  
Xuanbin Wang ◽  
Chen Li ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Patients ◽  
Adjuvant Treatment ◽  
Survival Benefit ◽  
Meta Analysis ◽  
Clinical Stage ◽  
Stage I ◽  
Metformin Therapy ◽  
Risk Of Death ◽  
Comprehensive Therapy

Background/Aims: Previous studies on the effect of metformin therapy on survival of pancreatic cancer patients obtained inconsistent findings. To reevaluate the prognostic value of metformin adjuvant treatment, a meta-analysis was carried out. Methods: Relevant articles addressing the association between metformin use and pancreatic cancer survival were electronically searched to identify eligible studies. Pooled hazard ratios (HRs) and 95% confidence intervals (95% CIs) were calculated to assess the strength of the association. Results: Totally, seventeen studies involving 36791 participants were included. Overall, metformin use was found to be significantly associated with a favorable OS (HR=0.88, 95% CI=0.80-0.97). Subgroup analyses by ethnicity showed a significantly reduced risk of death for metformin users compared with non-users in Asians (HR=0.74, 95% CI=0.58-0.94) but nonsignificant in Caucasians. When stratified by clinical stage, a remarkable reduction of mortality risk in patients at stage I-II treated with metformin (HR=0.76, 95% CI=0.68-0.86) was found as well as the group at stage I-IV (HR=0.88, 95% CI=0.79-0.99), but not in patients at stage III-IV. In the stratification analyses based on treatment strategy, metformin therapy was found to be associated with a better clinical outcome in patients receiving surgery or comprehensive therapy (HR=0.73, 95% CI=0.62-0.87; HR=0.88, 95% CI=0.79-0.97) but not chemotherapy. However, the overall analysis failed to show a significant association between metformin use and DFS (HR=1.54, 95% CI=0.94 -2.50) with only 2 studies enrolled. Conclusion: The current study has evidenced a significant association of metformin adjuvant treatment with the survival benefit for pancreatic cancer patients, suggesting a potentially available option for the treatment. Further investigation is needed.

scholarly journals ENO1 Overexpression in Pancreatic Cancer Patients and Its Clinical and Diagnostic Significance

2018 ◽  
Vol 2018 ◽  
pp. 1-7 ◽  
Author(s):  
Hang Yin ◽  
Lei Wang ◽  
Hai-Lin Liu
Keyword(s):  
Pancreatic Cancer ◽  
Lymph Node ◽  
Poor Prognosis ◽  
Diagnostic Marker ◽  
Clinical Stage ◽  
Healthy Controls ◽  
Diagnostic Significance ◽  
Node Metastasis ◽  
Homogeneous Assay ◽  
Electrochemiluminescence Immunoassay

We investigated in this study the expression of ENO1 in tissues and plasma of PDAC patients to evaluate its clinicopathological and diagnostic significance. ENO1 protein expression was detected in tissue microarray of human PDAC and adjacent noncancer tissues. Electrochemiluminescence immunoassay and amplified luminescent proximity homogeneous assay (AlphaLISA) were performed to measure CA19-9 and ENO1 concentration in plasma from PDAC patients and healthy controls. We demonstrated that ENO1 overexpression is positively correlated with clinical stage, lymph node metastasis, and poor prognosis of PDAC; ENO1 may function as a hopeful candidate diagnostic marker in combination with CA19-9 in PDAC diagnosis.

scholarly journals P-165 Specific changes in fecal microbiota may differentiate Pancreatic Cancer patients from healthy individuals

2015 ◽  
Vol 26 ◽  
pp. iv48 ◽  
Author(s):  
E. Half ◽  
N. Keren ◽  
T. Dorfman ◽  
L. Reshef ◽  
I. Lachter ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Patients ◽  
Fecal Microbiota ◽  
Healthy Individuals

scholarly journals Fluorescence Liquid Biopsy for Cancer Detection Is Improved by Using Cationic Dendronized Hyperbranched Polymer

2021 ◽  
Vol 22 (12) ◽  
pp. 6501
Author(s):  
Violeta Morcuende-Ventura ◽  
Sonia Hermoso-Durán ◽  
Natalia Abian-Franco ◽  
Roberto Pazo-Cid ◽  
Jorge L. Ojeda ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Cancer Patients ◽  
Liquid Biopsy ◽  
Classification Performance ◽  
Ductal Adenocarcinoma ◽  
Diagnostic Tools ◽  
Diagnostic Model ◽  
Healthy Individuals ◽  
Serum Samples

(1) Background: Biophysical techniques applied to serum samples characterization could promote the development of new diagnostic tools. Fluorescence spectroscopy has been previously applied to biological samples from cancer patients and differences from healthy individuals were observed. Dendronized hyperbranched polymers (DHP) based on bis(hydroxymethyl)propionic acid (bis-MPA) were developed in our group and their potential biomedical applications explored. (2) Methods: A total of 94 serum samples from diagnosed cancer patients and healthy individuals were studied (20 pancreatic ductal adenocarcinoma, 25 blood donor, 24 ovarian cancer, and 25 benign ovarian cyst samples). (3) Results: Fluorescence spectra of serum samples (fluorescence liquid biopsy, FLB) in the presence and the absence of DHP-bMPA were recorded and two parameters from the signal curves obtained. A secondary parameter, the fluorescence spectrum score (FSscore), was calculated, and the diagnostic model assessed. For pancreatic ductal adenocarcinoma (PDAC) and ovarian cancer, the classification performance was improved when including DHP-bMPA, achieving high values of statistical sensitivity and specificity (over 85% for both pathologies). (4) Conclusions: We have applied FLB as a quick, simple, and minimally invasive promising technique in cancer diagnosis. The classification performance of the diagnostic method was further improved by using DHP-bMPA, which interacted differentially with serum samples from healthy and diseased subjects. These preliminary results set the basis for a larger study and move FLB closer to its clinical application, providing useful information for the oncologist during patient diagnosis.

scholarly journals Based on Serum Raman and Fluorescence Spectra to Diagnose Liver Cancer

2022 ◽  
Author(s):  
Quanhong Ou ◽  
Xien Yang ◽  
Weiye Yang ◽  
Liqin Jiang ◽  
Kai Qian ◽  
...  
Keyword(s):  
Raman Spectroscopy ◽  
Liver Cancer ◽  
Cancer Patients ◽  
Raman Spectra ◽  
Fluorescence Spectra ◽  
Disease Diagnosis ◽  
Spectral Features ◽  
Healthy Individuals ◽  
Serum Samples ◽  
Biological Studies

Abstract Background: Raman and fluorescence spectra techniques are potential tools for disease diagnosis. In recent years, the application of Raman and fluorescence spectra techniques in biological studies has increased a great deal, and clinical investigations relevant to cancer detection by spectroscopic means have attracted particularly attention from both clinical and non-clinical researchers. Methods: In this article, Raman and fluorescence spectra were employed for the detection of liver cancer and healthy individuals using their serum samples. These serum samples were compared with their spectral features acquired by Raman and fluorescence spectroscopy to initially establish spectral features that can be considered spectral markers of liver cancer diagnosis. Resuits: The intensity differences from characteristic peaks of carotene, protein and lipid associated Raman spectra were clearly observed in liver cancer patient serum samples versus normal human serum. The changes in the serum fluorescence profiles of liver cancer patients were also analyzed. To probe the capacity and contrast of Raman spectroscopy as an analytical implement for the early diagnosis of liver cancer, principal component analysis (PCA) was used to analyze the Raman spectra of controls , liver cancer patients and healthy individuals. Furthermore, the Partial Least Squares-Discriminant Analysis (PLS-DA) was performed to compare the diagnostic performance of Raman spectroscopy for the classification of disease samples and healthy samples.Conclusion: Compare with the existing diagnostic techniques, the Raman spectroscopy technique has an excellent advantage in extremely low sample requirements, ease of use and ideal screening procedures. Thus, Raman spectroscopy has great potential to be developed as a powerful tool for distinguishing between healthy and liver cancer serum samples.

SUN-PP119: Leptin as a Diagnostic Marker of Cachexia Predict Survival in Pancreatic Cancer Patients

2015 ◽  
Vol 34 ◽  
pp. S67
Author(s):  
A. Saray ◽  
N. Vanis ◽  
S. Glavas ◽  
N. Zahiragic ◽  
R. Mesihovic
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Patients ◽  
Diagnostic Marker
Sign in / Sign up

Export Citation Format

Share Document